Nonalcoholic fatty liver disease (NAFLD) is a major clinical consequence for people with obesity and metabolic syndrome and is also associated with enteral and parenteral nutrition. Early studies suggested that altered gut microbiota might contribute to obesity by affecting energy harvest from the diet and energy storage in the host. Recent evidence in humans as well as in animal models has linked gut microbiota to the development of NAFLD through the gut-liver axis. With bacterial overgrowth and increased intestinal permeability observed in patients with NAFLD and in animal models, gut-derived bacterial products such as endotoxin (lipopolysaccharide) and bacterial DNA are being delivered to the liver through the portal vein and then activate Toll-like receptors (TLRs), mainly TLR4 and TLR9, and their downstream cytokines and chemokines, leading to the development and progression of NAFLD. Given the limited data in humans, the role of gut microbiota in the pathogenesis of NAFLD is still open to discussion. Prebiotics and probiotics have been attempted to modify the microbiota as preventive or therapeutic strategies on this pathological condition. Their beneficial effects on NALFD have been demonstrated in animal models and limited human studies. However, prospective, appropriately powered, randomized, controlled clinical trials are needed to determine whether prebiotics and probiotics and other integrated strategies to modify intestinal microbiota are efficacious therapeutic modalities to treat NALFD.
FlegalKMCarrollMDKitBKOgdenCL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491-497.
2.
OgdenCLCarrollMDKitBKFlegalKM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA. 2012;307:483-490.
3.
VernonGBaranovaAYounossiZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285.
4.
MieleLValenzaVLa TorreG. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877-1887.
5.
EckburgPBBikEMBernsteinCN. Diversity of the human intestinal microbial flora. Science. 2005;308:1635-1638.
6.
SharmaRYoungCNeuJ. Molecular modulation of intestinal epithelial barrier: contribution of microbiota. J Biomed Biotechnol. 2010;2010:305879.
7.
StappenbeckTSHooperLVGordonJI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A. 2002;99:15451-15455.
MacphersonAJUhrT. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004;303:1662-1665.
10.
CeruttiARescignoM. The biology of intestinal immunoglobulin A responses. Immunity. 2008;28:740-750.
11.
VinoloMARodriguesHGNachbarRTCuriR. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3:858-876.
12.
HooperLVStappenbeckTSHongCVGordonJI. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol. 2003;4:269-273.
13.
SalzmanNHHungKHaribhaiDChuHKarlsson-SjöbergJAmirE. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol. 2010;11:76-83.
14.
BouskraDBrézillonCBérardM. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature. 2008;456:507-510.
15.
Gaboriau-RouthiauVRakotobeSLécuyerE. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009;31:677-689.
16.
ClarkeTBDavisKMLysenkoESZhouAYYuYWeiserJN. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med. 2010;16:228-231.
17.
KinrossJMDarziAWNicholsonJK. Gut microbiome-host interactions in health and disease. Genome Med. 2011;3:14.
18.
KellyCRde LeonLJasutkarN. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol. 2012;46:145-149.
19.
MattilaEUusitalo-SeppäläRWuorelaM. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142:490-496.
20.
ShimizuKOguraHHamasakiT. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci. 2011;56:1171-1177.
21.
MurakoshiSFukatsuKOmataJ. Effects of adding butyric acid to PN on gut-associated lymphoid tissue and mucosal immunoglobulin A levels. JPEN J Parenter Enteral Nutr. 2011;35:465-472.
22.
QinJLiRRaesJ. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65.
23.
BäckhedFDingHWangT. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101:15718-15723.
24.
de La SerreCBEllisCLLeeJHartmanALRutledgeJCRaybouldHE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010;299:G440-G448.
25.
LeyREBäckhedFTurnbaughPLozuponeCAKnightRDGordonJI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102:11070-11075.
26.
TurnbaughPJLeyREMahowaldMAMagriniVMardisERGordonJI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027-1031.
27.
TurnbaughPJHamadyMYatsunenkoT. A core gut microbiome in obese and lean twins. Nature. 2009;457:480-484.
28.
CompareDCoccoliPRoccoA. Gut–liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2012;22:471-476.
29.
WiggAJRoberts-ThomsonICDymockRBMcCarthyPJGroseRHCumminsAG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48:206-211.
30.
SabatéJMJouëtPHarnoisF. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg. 2008;18:371-377.
31.
ShanabAAScullyPCrosbieO. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with Toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci. 2011;56: 1524-1534.
32.
StenmanLKHolmaRKorpelaR. High-fat–induced intestinal permeability dysfunction associated with altered fecal bile acids. World J Gastroenterol. 2012;18:923-929.
33.
YangSQLinHZLaneMDClemensMDiehlAM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997;94:2557-2562.
34.
PeyretBCollardeauSTouzetS. Prevalence of liver complications in children receiving long-term parenteral nutrition. Eur J Clin Nutr. 2011;65:743-749.
35.
StollBHorstDACuiL. Chronic parenteral nutrition induces hepatic inflammation, steatosis, and insulin resistance in neonatal pigs. J Nutr. 2010;140:2193-2200.
36.
StollBPuimanPJCuiL. Continuous parenteral and enteral nutrition induces metabolic dysfunction in neonatal pigs. JPEN J Parenter Enteral Nutr. 2012;36:538-550.
37.
BaumgardnerJNShankarKHenningsLBadgerTMRonisMJ. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol. 2008;294:G27-G38.
38.
TillmanEM. Review and clinical update on parenteral nutrition-associated liver disease. Nutr Clin Pract. 2013;28:30-39.
39.
SzaboGVelayudhamARomicsLJrMandrekarP. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of Toll-like receptors 2 and 4. Alcohol Clin Exp Res. 2005;29(11)(suppl):140S-145S.
40.
RiveraCAAdegboyegaPvan RooijenNTagalicudAAllmanMWallaceM. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47:571-579.
41.
GuerrerioALColvinRMSchwartzAK. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr. 2012;95:892-900.
42.
BuchmanALDubinMDMoukarzelAA. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology. 1995;22:1399-1403.
43.
BuchmanALAmentMESohelM. Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial. JPEN J Parenter Enteral Nutr. 2001;25:260-268.
44.
SpencerMDHampTJReidRWFischerLMZeiselSHFodorAA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology. 2011;140:976-986.
45.
DumasMEBartonRHToyeA. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006;103:12511-12516.
46.
OuyangXCirilloPSautinY. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48:993-999.
47.
ThuySLadurnerRVolynetsV. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008;138:1452-1455.
48.
BergheimIWeberSVosM. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol. 2008;48:983-992.
49.
SprussAKanuriGWagnerbergerSHaubSBischoffSCBergheimI. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009;50:1094-1104.
50.
HodinCMVisschersRGRensenSS. Total parenteral nutrition induces a shift in the Firmicutes to Bacteroidetes ratio in association with Paneth cell activation in rats. J Nutr. 2012;142:2141-2147.
51.
RuizAGCasafontFCrespoJ. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17:1374-1380.
VerdamFJRensenSSDriessenAGreveJWBuurmanWA. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J Clin Gastroenterol. 2011;45:149-152.
54.
PoniachikJCsendesADíazJC. Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine. 2006;33: 252-257.
55.
YeDLiFYLamKS. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut. 2012;61:1058-1067.
56.
LiLChenLHuL. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology. 2011;54:1620-1630.
57.
LeeSHongJChoiSY. CpG oligodeoxynucleotides induce expression of proinflammatory cytokines and chemokines in astrocytes: the role of c-Jun N-terminal kinase in CpG ODN-mediated NF-kappaB activation. J Neuroimmunol. 2004;153:50-63.
58.
MiuraKKodamaYInokuchiS. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010;139:323-334.e7.
59.
CsakTGanzMPespisaJKodysKDolganiucASzaboG. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011;54:133-144.
60.
Henao-MejiaJElinavEJinCHaoLMehalWZ. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179-185.
61.
HimesRWSmithCW. Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB J. 2010;24:731-739.
BraunersreutherVVivianiGLMachFMontecuccoF. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18:727-735.
64.
DaubioulCAHorsmansYLambertPDanseEDelzenneNM. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr. 2005;59: 723-726.
65.
HolscherHDFaustKLCzerkiesLA. Effects of prebiotic-containing infant formula on gastrointestinal tolerance and fecal microbiota in a randomized controlled trial. JPEN J Parenter Enteral Nutr. 2012;36(1)(suppl):95S-105S.
FanJGXuZJWangGL. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World J Gastroenterol. 2005;11: 5053-5056.
68.
CaniPDPossemiersSVan de WieleT. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58:1091-1103.
69.
FukudaMKomiyamaYMitsuyamaK. Prebiotic treatment reduced preneoplastic lesions through the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model. J Clin Biochem Nutr. 2011;49: 57-61.
AllerRDe LuisDAIzaolaO. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15: 1090-1095.
72.
LiZYangSLinH. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343-350.
73.
VelayudhamADolganiucAEllisM. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. 2009;49 :989-997.
74.
XuRYWanYPFangQYLuWCaiW. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr. 2012;50:72-77.
75.
KarahanNIşlerMKoyuA. Effects of probiotics on methionine choline deficient diet-induced steatohepatitis in rats. Turk J Gastroenterol. 2012;23:110-121.
76.
MencarelliACiprianiSRengaB. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One. 2012;7:e45425.
77.
BakerSSBakerRDLiuWNowakNJZhuL. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One. 2010;5:e9570.
78.
VolynetsVKüperMAStrahlS. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2012;57:1932-1941.
79.
ZhuLBakerSSGillC. Characterization of the gut microbiome in non-alcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601-609.
80.
Abu-ShanabAQuigleyEM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:691-701.
81.
IaconoARasoGMCananiRBCalignanoAMeliR. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22:699-711.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
